Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Ocular Therapeutix (OCUL) Debt to Equity (2016 - 2025)

Ocular Therapeutix has reported Debt to Equity over the past 13 years, most recently at $0.11 for Q4 2025.

  • Quarterly results put Debt to Equity at $0.11 for Q4 2025, down 49.81% from a year ago — trailing twelve months through Dec 2025 was $0.11 (down 49.81% YoY), and the annual figure for FY2025 was $0.11, down 49.81%.
  • Debt to Equity for Q4 2025 was $0.11 at Ocular Therapeutix, down from $0.27 in the prior quarter.
  • Over the last five years, Debt to Equity for OCUL hit a ceiling of $8.29 in Q3 2023 and a floor of $0.11 in Q4 2025.
  • Median Debt to Equity over the past 5 years was $0.28 (2021), compared with a mean of $1.19.
  • Biggest five-year swings in Debt to Equity: soared 1876.8% in 2023 and later tumbled 97.68% in 2024.
  • Ocular Therapeutix's Debt to Equity stood at $0.28 in 2021, then surged by 151.29% to $0.71 in 2022, then rose by 1.12% to $0.72 in 2023, then plummeted by 69.91% to $0.22 in 2024, then crashed by 49.81% to $0.11 in 2025.
  • The last three reported values for Debt to Equity were $0.11 (Q4 2025), $0.27 (Q3 2025), and $0.23 (Q2 2025) per Business Quant data.